The benefit was driven primarily by lower rates of new-onset persistent macroalbuminuria in low- to moderate-risk CKD and slower eGFR decline in high-risk CKD, with consistent findings across all other subgroups
Efficacy estimands were those reported at 52 weeks [15, 16, 18], or at 56 weeks in the case of the SUSTAIN 2 [17] trial (Appendix Table 5)
State guides About these guides Cash telehealth prices are set nationally, so a Texas resident pays the same cash price as a patient in New York
Ensure the pen does not directly contact ice packs to prevent freezing, and track any time spent at room temperature toward the 21-day limit
GLP-1 medications are generally well-tolerated, but they're not without side effects
Because retatrutide represents a major evolutionary leap over existing therapies, its commercial launch will likely disrupt the entire metabolic market